YOU STOPPED AT: “ Testing frequency: ├─ Can extend to every 6-12 months ├─"

COMPLETING YOUR 5-YEAR SURVEILLANCE PLAN

Let me finish the Phase 3 timeline and then provide you with the complete picture of what to expect long-term.

---

PHASE 3: MONTHS 24-60 (Years 3-5 Post-Op) - COMPLETE

Testing frequency:
├─ Can extend to every 6-12 months
├─ Depends on continued undetectable PSA
├─ If PSA remains <0.01 ng/mL: Annual testing acceptable
├─ If PSA rises toward 0.05 ng/mL: Return to 3-month intervals
└─ Flexibility based on your PSA pattern

Specific timeline for your case:

YEAR 3 (May 2028 - 36 months post-op):
├─ PSA testing: Every 6 months
├─ May 2028: PSA check
├─ November 2028: PSA check
├─ Expected results: 0.005-0.015 ng/mL
└─ Clinical assessment: DRE (digital rectal exam) optional

YEAR 4 (May 2029 - 48 months post-op):
├─ PSA testing: Every 6-12 months
├─ May 2029: PSA check
├─ November 2029: PSA check (optional)
├─ Expected results: 0.005-0.015 ng/mL
└─ Clinical assessment: DRE optional

YEAR 5 (May 2030 - 60 months post-op):
├─ PSA testing: Every 12 months
├─ May 2030: PSA check
├─ Expected results: 0.005-0.015 ng/mL
└─ Clinical assessment: DRE optional

Phase 3 goal:
├─ Confirm long-term disease control
├─ Assess 5-year recurrence-free status
├─ Transition to annual monitoring
└─ Provide long-term reassurance

---

PHASE 4: BEYOND 5 YEARS (Lifelong Surveillance)

LONG-TERM SURVEILLANCE (Year 5+):

Testing frequency:
├─ PSA every 12 months indefinitely
├─ DRE: Optional, based on preference
├─ Imaging: Only if PSA rises
└─ Duration: For life

Why lifelong surveillance?
├─ Prostate cancer can recur years later
├─ Late recurrences occur in 5-10% of cases
├─ PSA is sensitive marker for recurrence
├─ Early detection allows effective salvage therapy
├─ Risk never reaches zero
└─ Surveillance is low-burden, high-value

Your expected PSA pattern:
├─ Years 1-5: 0.005-0.015 ng/mL (stable)
├─ Years 5-10: 0.005-0.015 ng/mL (stable)
├─ Years 10+: 0.005-0.015 ng/mL (stable)
└─ If rises above 0.05: Requires investigation

Milestone assessments:
├─ 5-year mark (May 2030): Major reassurance point
│  └─ 70-80% remain cancer-free
├─ 10-year mark (May 2035): Excellent prognostic sign
│  └─ 60-70% remain cancer-free
└─ 15-year mark (May 2040): Very favorable outcome
   └─ 50-60% remain cancer-free

---

WHAT HAPPENS IF YOUR PSA RISES? - DECISION TREE

Your Action Plan Based on PSA Results

According to NCCN Guidelines for PSA Recurrence After Prostatectomy:

SCENARIO 1: PSA REMAINS <0.01 ng/mL (Most Likely - 85-90%)

Result: EXCELLENT
├─ Status: Undetectable PSA
├─ Interpretation: No recurrence
├─ Action: Continue routine surveillance
├─ Next PSA: Per schedule (3-6 months initially)
├─ Imaging: None needed
├─ Treatment: None needed
└─ Your message: "Everything is on track"

What this means:
├─ You're in the 70-80% who won't recur
├─ Your surgery was successful
├─ Benign tissue PSA is stable
├─ Continue current monitoring plan
└─ Excellent long-term prognosis

SCENARIO 2: PSA 0.01-0.05 ng/mL (Possible - 5-8%)

Result: BORDERLINE - REQUIRES CONFIRMATION
├─ Status: Detectable but low
├─ Interpretation: Could be benign variation OR early signal
├─ Action: Repeat PSA in 4-6 weeks
├─ Next PSA: Urgent repeat (not routine schedule)
├─ Imaging: None yet - wait for confirmation
├─ Treatment: None yet - wait for confirmation
└─ Your message: "Need to recheck - probably nothing"

Decision tree if this occurs:

If repeat PSA (4-6 weeks later):
├─ Returns to <0.01 ng/mL
│  ├─ Interpretation: Benign variation
│  ├─ Action: Return to routine surveillance
│  ├─ Next PSA: Per schedule
│  └─ Reassurance: High
│
├─ Stays at 0.01-0.05 ng/mL
│  ├─ Interpretation: Possible early signal
│  ├─ Action: Repeat again in 4 weeks
│  ├─ Next PSA: Another urgent repeat
│  └─ Reassurance: Moderate
│
└─ Rises above 0.05 ng/mL
   ├─ Interpretation: Recurrence signal
   ├─ Action: Imaging and further evaluation
   ├─ Next step: PSMA-PET scan
   └─ Reassurance: Low - needs investigation

Key point:
A single borderline PSA is NOT recurrence.
You need a TREND (rising values) or confirmation.

SCENARIO 3: PSA 0.05-0.20 ng/mL (Unlikely - 2-4%)

Result: ELEVATED - REQUIRES INVESTIGATION
├─ Status: Clearly detectable
├─ Interpretation: Possible early recurrence
├─ Action: Urgent repeat PSA + imaging
├─ Next PSA: Repeat within 1-2 weeks
├─ Imaging: PSMA-PET scan recommended
├─ Treatment: None yet - wait for confirmation
└─ Your message: "Need to investigate further"

Decision tree if this occurs:

Step 1: Confirm with repeat PSA (1-2 weeks)
├─ If returns to <0.01 ng/mL
│  ├─ Interpretation: Lab error or benign variation
│  ├─ Action: Return to routine surveillance
│  └─ Reassurance: High
│
└─ If stays elevated or rises
   ├─ Interpretation: Recurrence likely
   ├─ Action: Proceed to imaging
   └─ Reassurance: Low - needs workup

Step 2: Imaging (if PSA confirmed elevated)
├─ PSMA-PET scan (primary imaging)
│  ├─ Purpose: Locate cancer cells
│  ├─ Sensitivity: 85-95% for recurrent disease
│  ├─ Shows: Local recurrence vs. metastatic disease
│  └─ Guides: Treatment planning
│
├─ MRI pelvis (if PSMA-PET negative)
│  ├─ Purpose: Assess local recurrence
│  ├─ Sensitivity: 70-80% for local disease
│  └─ Shows: Recurrence in prostate bed
│
└─ Bone scan (if bone metastases suspected)
   ├─ Purpose: Detect bone involvement
   ├─ Sensitivity: 80-90% for bone disease
   └─ Shows: Extent of bone met